New York, USA – October 9, 2020 – Microbiosci, the division of Creative Biogene, focuses on offering a wide range of high-quality products and services in microbial genome editing, identification, sequencing, proteomics and metabolomics aiming to facilitate the investigation of microbial researches. Recently Microbiosci announces the release of its microbial community analysis in order to provide powerful, comprehensive solutions for microbiota analysis.
Microbial community analysis investigates a large amount of theoretical and practical knowledge about the design of biological treatment systems. It describes the different types of biological wastewater systems, the role of microbial diversity in these systems, and how this affects design and operation, methods for studying microbial community dynamics, and mathematical models of these systems.
Microbiosci provides the most advanced microbial community analysis services. With the microbial community analysis service, scientists can identify thousands of microorganisms in one analysis and determine their relative abundance. Nowadays, microbial community analysis is essential to the development of human and animal health, nutrition, environment and biotechnology research.
The microbial community analysis service based on PCR and Next Generation Sequencing (NGS) technology provides multiple possibilities for microbial identification and microbial diversity research. Microbiosci provides complete microbial community analysis services, including DNA extraction from a series of samples such as intestinal tract, skin, probiotics, water or soil samples. By using PCR and NGS technology, Microbiosci can determine the composition of bacteria, archaea and fungi in the sample.
Microorganisms play a key role in the metabolism of the host and are considered a potential source of new treatments. Several diseases are now believed to be affected by the process of the gut microbiome, including cancer, autoimmune diseases such as multiple sclerosis and autism spectrum diseases.
Microbiosci provides a broad portfolio of microbiome analysis products, including not only consulting, research design, sampling solutions, and sequencing, but also downstream bioinformatics and biostatistics analysis. With Next-Generation Sequencing (NGS) technology, Microbiosci has the tools to analyze the human gut microbiome. With this high-throughput technology, complete metagenomics research can be conducted, enabling the investigation of the genomes of entire communities, including those of organisms that cannot be cultivated.
In addition, the characterization of skin microbiota is essential for diagnosing skin conditions. The interacting symbiosis and immunity in the skin can predict disease risk and probiotic efficacy. Skin microorganisms also produce compounds that affect the physiology of the host. The research on the skin microbiome provides an opportunity to understand the relationship between microorganisms and human skin diseases, and provides novel antibacterial and antibacterial treatment methods for their treatment. Microbiosci provides a complete solution to prove the true efficacy of specific products on the microbiome.
“Microbiosci provides a powerful and comprehensive solution for microbiota analysis, which will promote your research and provide you with a huge beneficial choice for microbial genomics in the future!” said Marcia Brady, the marketing director of Creative Biogene.
Microbiosci, as the division of Creative Biogene, is always dedicated to satisfying the needs of clients covering more than 50 countries and districts. As a leading custom service provider in delivering medicine microbiology solutions, Microbiosci has become a well-recognized industry leader with years of experience and professional scientists.